MANGALAMMangalam Drugs & OrganicsMANGALAM info
$1.60info1.28%24h
Global rank28965
Market cap$25.30M
Change 7d6.26%
YTD Performance34.82%
SP500 benchmarkOutperform
P/E2.00
P/S0.58
Revenue$43.60M
Earnings$151.30K
Dividend yield-
Main Sector
Healthcare

Mangalam Drugs & Organics (MANGALAM) Stock Overview

Mangalam Drugs & Organics Limited manufactures and sells active pharmaceutical ingredients (APIs) and intermediates in India. It offers a range of API products, which include Acyclovir, Amodiaquine, Artemether, Artesunate, Atazanavir Sulfate, Bisoprolol Fumarate, Chloroquine Phosphate, Dihydroartemisinin, and Dolutegravir Sodium; Efavirenz, Emtricitabine, Furosemide, Hydroxychloroquine Sulphate, Lumefantrine, and Nimesulide; Nitrofurantoin Anhydrous and Monohydrate; Primaquine and Piperaquine Phosphate; Pregabalin, Pyrimethamine, Pyronaridine Tetraphosphate, and Sulfadoxine; and Tenofovir Alafenamide Hemifumarate and Disoproxil Fumarate. The company also offers intermediates comprising 2-Dibutylamino-1-(2,7-dichloro-9H-fluorine-4-yl)-ethanol; 4,6-Dichloro-5-methoxy pyrimidine; 4,7 Dichloroquinoline; Ortho phenoxy methane sulfonanilide; and Tenofovir Alafenamide Base and Disoproxil Base. In addition, it offers specialty chemicals, such as Menthol; 2,3-Dihydrophthalazine-1, 4-dione; and 4-cynoethyl-2-methyl phenol. Further, the company's products under development include Tafenoquine Succinate, Bictegravir Na, Favipiravir, and Molnupiravir; and Elvitegravir, Cobicistat, Daclatasvir dihydrochloride, Ledipasvir, and Velpatasvir. The company was incorporated in 1972 and is based in Mumbai, India.

MANGALAM Stock Information

Symbol
MANGALAM
Address
Rupam BuildingMumbai, 400001India
Founded
-
Trading hours
-
Website
https://www.mangalamdrugs.com
Country
🇮🇳 India
Phone Number
91 22 6261 6200

Mangalam Drugs & Organics (MANGALAM) Price Chart

-
Value:-

Mangalam Drugs & Organics Overview: Key Details and Summary

Stock data
2023
Change
Price
$1.60
N/A
Market Cap
$25.30M
N/A
Shares Outstanding
15.83M
0.00%
Employees
523.00
N/A
Shareholder Equity
1.52B
0.93%
Valuation
2023
Change
P/E Ratio
2.00
N/A
P/S Ratio
0.58
N/A
P/B Ratio
0.02
N/A
Growth
2023
Change
Return on Equity
0.0001
N/A
Earnings
2023
Change
Revenue
$43.60M
N/A
Earnings
$151.30K
N/A
EPS
0.8
N/A
Earnings Yield
0.5006
N/A
Gross Margin
0.1917
N/A
Operating Margin
0.0399
N/A
Net income margin
0.0035
N/A
Financial Strength
2023
Change
Total Assets
$42.84M
N/A
Total Debt
$10.55M
N/A
Cash on Hand
$320.26K
N/A
Debt to Equity
0.0163
15.69%
Cash to Debt
0.0304
36.55%
Current Ratio
$1.25
-12.15%
logo
Facebook Icon
Twitter Icon
Linkedin Icon
© 2024 Topstocks.org